▲ From left to right, Kim Jun-young, Head of Pre-Technology Research Institute at Plasmapp; David Kim, Professor at Harvard University (top right); Marty Trabish, CEO of Plasmapp America; Professor Stefano from Parma University in Italy; former Harvard University Professor Nevins.

Bio plasma deep tech company Plasmapp (CEO Youbong Lim) has embarked on a leap to become a global deep tech technology company.

Plasmapp's U.S. subsidiary, Plasmapp America (represented by Marty Trabish and Han Seung-jin), recently signed two joint research and development contracts worth 1.3 billion won with leading global companies and began animal experiments.

This experiment has garnered attention as prominent scholars in the dental field, including Dr. Nevins, former chairman of the American Academy of Periodontology and Harvard professor; Dr. David Kim, a Harvard University professor who also serves as a consultant for Plasmapp; and Dr. Stefano from Parma University in Italy, are participating.

Plasmapp plans to secure references for its groundbreaking plasma bio regenerative technology, "Bio Activation," and build trust in this technology. Recently, Plasmapp America signed a contract worth 700 million won with Israeli implant company "Ditron Implant."

Ditron Implant is a globally renowned implant specialist with a 50-year history. Plasmapp will integrate Ditron's "Antimicrobial" technology with its plasma bio regenerative technology and begin joint experiments and product development.

Dr. Ole Jensen, founder and president of Ditron Dental USA, who led the contract, expressed optimism, stating that the integration of Ditron's new technology with Plasmapp's bio regenerative technology will shape the future of the dental industry.

In connection with this, Professor Stefano, who participated in the experiment, evaluated that "Plasmapp's technology can be easily and effectively integrated into new implant technologies, including Ditron's new technology."

Plasmapp America also signed a contract worth 600 million won with Lucid, a U.S. medical technology innovation company. As a result, they aim to develop products that can synergize with Lucid's low-temperature drill technology.

Marty Trabish, co-CEO of Plasmapp America, stated, "This joint research and development contract will be more than just conducting animal experiments; it will serve as an opportunity to complement and advance implant technology." He added, "Based on this, we will continue to discuss ongoing technological collaborations with global implant companies in the dental and orthopedic fields."

Meanwhile, Plasmapp America, a subsidiary wholly owned by Plasmapp, plays a bridging role in securing successful references for Plasmapp and leading collaboration with global major companies.

▲ From left: ACTILINK motion and ACTILINK mini devices for dental implants.

Source: Dailymedi ( www.dailymedi.com )